Abstract
Clinical evidence in chronic myeloid leukemia demonstrates a significant link between optimal response to tyrosine kinase inhibitor (TKI) therapy and favorable clinical outcome. For patients with suboptimal response to first-line TKI, clinical data show that a considerable proportion can be rescued by second-line TKI. Practice guidelines now recommend that clinicians consider a switch in TKI for patients with suboptimal response as early as 3 months after first-line TKI initiation, thus allowing clinicians to intervene in a timely manner and consider the potential benefit of a switch in TKI therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 487-495 |
Number of pages | 9 |
Journal | Leukemia Research |
Volume | 37 |
Issue number | 5 |
DOIs | |
State | Published - May 2013 |
Keywords
- Adverse drug event
- Chronic myeloid leukemia
- Dasatinib
- Drug resistance
- Imatinib
- Nilotinib
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research